Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (181-190 of 459) with videos related to

Pageof 46
Sort By:
Cells|April 9, 2014
Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor ProgressionSonia Liberati, Maria Beatrice Morelli, Consuelo Amantini, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 29, 2014
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinibRoberto Iacovelli, Giacomo Cartenì, Michele Milella, et al.
Critical Reviews in Oncology/Hematology|January 15, 2022
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 studyMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Cells|June 25, 2020
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate CancerAlessia Cimadamore, Gaetano Aurilio, Franco Nolé, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 19, 2019
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic ImplicationsMatteo Santoni, Giulia Occhipinti, Emanuela Romagnoli, et al.
International Journal of Molecular Sciences|February 9, 2021
Treating Prostate Cancer by Antibody-Drug ConjugatesMatteo Rosellini, Matteo Santoni, Veronica Mollica, et al.
Frontiers in Oncology|August 8, 2022
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest DevelopmentsGiandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Clinical Nutrition ESPEN|November 6, 2025
Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): The MOUSEION-012 systematic review and meta-analysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Future Oncology (London, England)|January 10, 2020
Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapyAlessia Cimadamore, Antonio Lopez-Beltran, Francesco Massari, et al.
Cancer Metastasis Reviews|December 17, 2013
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedsideMatteo Santoni, Daniele Santini, Francesco Massari, et al.
Pageof 46

Showing results (181-190 of 459) with videos related to

Sort By:
Pageof 46
Cells|April 9, 2014
Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor ProgressionSonia Liberati, Maria Beatrice Morelli, Consuelo Amantini, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 29, 2014
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinibRoberto Iacovelli, Giacomo Cartenì, Michele Milella, et al.
Critical Reviews in Oncology/Hematology|January 15, 2022
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 studyMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Cells|June 25, 2020
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate CancerAlessia Cimadamore, Gaetano Aurilio, Franco Nolé, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 19, 2019
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic ImplicationsMatteo Santoni, Giulia Occhipinti, Emanuela Romagnoli, et al.
International Journal of Molecular Sciences|February 9, 2021
Treating Prostate Cancer by Antibody-Drug ConjugatesMatteo Rosellini, Matteo Santoni, Veronica Mollica, et al.
Frontiers in Oncology|August 8, 2022
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest DevelopmentsGiandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Clinical Nutrition ESPEN|November 6, 2025
Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): The MOUSEION-012 systematic review and meta-analysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Future Oncology (London, England)|January 10, 2020
Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapyAlessia Cimadamore, Antonio Lopez-Beltran, Francesco Massari, et al.
Cancer Metastasis Reviews|December 17, 2013
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedsideMatteo Santoni, Daniele Santini, Francesco Massari, et al.
Pageof 46